<p>Covaxin is showing an overall efficiency of 77.8% against Covid-19 and is 93.4% effective in severe cases of infection, said Bharat Biotech on Saturday, revealing the final Phase-3 trial results of the vaccine's safety and efficacy.</p>.<p>The indigenous Covid-19 vaccine is offering 63.6% security in asymptomatic cases, and is also demonstrating 65.2% protection against the Delta variant infection, the Hyderabad-based vaccine maker announced in a joint statement with Indian Council of Medical Research (ICMR) on Saturday.</p>.<p>“Covaxin is the first licensed SARS-CoV-2 vaccine to report promising efficacy against asymptomatic infections based on qPCR testing that will help in reducing disease transmission,” Bharat Biotech said.</p>.<p><a href="https://www.deccanherald.com/national/indias-daily-covid-cases-under-50000-for-6th-straight-day-1004351.html" target="_blank"><strong>Read | India's daily Covid cases under 50,000 for 6th straight day</strong></a></p>.<p>B.1.617.2 aka Delta, classified as a "Variant of Concern" by the World Health Organization, is reported as the coronavirus variant primarily responsible for the Covid-19 second wave in the country.</p>.<p>“Covaxin is working well against all variant strains of SARS-CoV-2. Covaxin's successful development has consolidated the position of Indian academia and industry in the global arena,” said Prof Balram Bhargava, Secretary, Department of Health Research & Director General, ICMR.</p>.<p>The much awaited Phase-3 clinical trial results were revealed exactly six months after the vaccine developed in public-private partnership was accorded the emergency use authorization by the Drugs Controller General of India on 3 January.</p>.<p>However, the results based on the event driven analysis of 130 symptomatic Covid-19 cases, reported at least two weeks after the 2nd dose, are yet to be peer reviewed. The study outcomes are published on preprint server MedRxiv.</p>.<p><a href="https://www.deccanherald.com/national/how-india-could-have-averted-13-crore-covid-19-cases-11-lakh-deaths-1004199.html" target="_blank"><strong>Also Read | How India could have averted 1.3 crore Covid-19 cases, 1.1 lakh deaths</strong></a></p>.<p>Phase-3 trials of Covaxin were conducted between November 2020 and February 2021, on 25,800 volunteers across the country, in what Bharat Biotech claimed is “the largest Phase-3 efficacy trial ever conducted for any vaccine in India.”</p>.<p>Around 12 percent of the 34 crore Covid-19 vaccine doses administered in the country till now are Covaxin and the rest are Oxford-AstraZeneca developed and Serum Institute of India, Pune manufactured Covishield. Russian made Sputnik V, the third vaccine approved in India in April, is yet to be made available commercially.</p>.<p>The efficacy of Covishield was pegged at 70.42 % by the DCGI, while Sputnik V, as per an article in The Lancet, was found to be displaying 91.6 percent efficacy against Covid-19 infection.</p>.<p><a href="https://www.deccanherald.com/metrolife/metrolife-cityscape/third-covid-wave-wont-be-so-bad-say-bengaluru-doctors-1004201.html" target="_blank"><strong>Also See | Third Covid wave won't be so bad, say Bengaluru doctors</strong></a></p>.<p>Bharat Biotech said the overall rate of adverse events observed with Covaxin was lower than evident in other Covid-19 vaccines. “Safety analysis demonstrates adverse events reported were similar to placebo, with 12 % of subjects experiencing commonly known side effects and less than 0.5 % of subjects feeling serious adverse events”</p>.<p>In the second interim analysis from Phase-3 trials put out in April, Bharat Biotech and ICMR stated that Covaxin was showing overall clinical efficacy of 78 percent and 100 percent efficacy against severe Covid-19 infections.</p>.<p><strong>Check out DH latest videos:</strong></p>
<p>Covaxin is showing an overall efficiency of 77.8% against Covid-19 and is 93.4% effective in severe cases of infection, said Bharat Biotech on Saturday, revealing the final Phase-3 trial results of the vaccine's safety and efficacy.</p>.<p>The indigenous Covid-19 vaccine is offering 63.6% security in asymptomatic cases, and is also demonstrating 65.2% protection against the Delta variant infection, the Hyderabad-based vaccine maker announced in a joint statement with Indian Council of Medical Research (ICMR) on Saturday.</p>.<p>“Covaxin is the first licensed SARS-CoV-2 vaccine to report promising efficacy against asymptomatic infections based on qPCR testing that will help in reducing disease transmission,” Bharat Biotech said.</p>.<p><a href="https://www.deccanherald.com/national/indias-daily-covid-cases-under-50000-for-6th-straight-day-1004351.html" target="_blank"><strong>Read | India's daily Covid cases under 50,000 for 6th straight day</strong></a></p>.<p>B.1.617.2 aka Delta, classified as a "Variant of Concern" by the World Health Organization, is reported as the coronavirus variant primarily responsible for the Covid-19 second wave in the country.</p>.<p>“Covaxin is working well against all variant strains of SARS-CoV-2. Covaxin's successful development has consolidated the position of Indian academia and industry in the global arena,” said Prof Balram Bhargava, Secretary, Department of Health Research & Director General, ICMR.</p>.<p>The much awaited Phase-3 clinical trial results were revealed exactly six months after the vaccine developed in public-private partnership was accorded the emergency use authorization by the Drugs Controller General of India on 3 January.</p>.<p>However, the results based on the event driven analysis of 130 symptomatic Covid-19 cases, reported at least two weeks after the 2nd dose, are yet to be peer reviewed. The study outcomes are published on preprint server MedRxiv.</p>.<p><a href="https://www.deccanherald.com/national/how-india-could-have-averted-13-crore-covid-19-cases-11-lakh-deaths-1004199.html" target="_blank"><strong>Also Read | How India could have averted 1.3 crore Covid-19 cases, 1.1 lakh deaths</strong></a></p>.<p>Phase-3 trials of Covaxin were conducted between November 2020 and February 2021, on 25,800 volunteers across the country, in what Bharat Biotech claimed is “the largest Phase-3 efficacy trial ever conducted for any vaccine in India.”</p>.<p>Around 12 percent of the 34 crore Covid-19 vaccine doses administered in the country till now are Covaxin and the rest are Oxford-AstraZeneca developed and Serum Institute of India, Pune manufactured Covishield. Russian made Sputnik V, the third vaccine approved in India in April, is yet to be made available commercially.</p>.<p>The efficacy of Covishield was pegged at 70.42 % by the DCGI, while Sputnik V, as per an article in The Lancet, was found to be displaying 91.6 percent efficacy against Covid-19 infection.</p>.<p><a href="https://www.deccanherald.com/metrolife/metrolife-cityscape/third-covid-wave-wont-be-so-bad-say-bengaluru-doctors-1004201.html" target="_blank"><strong>Also See | Third Covid wave won't be so bad, say Bengaluru doctors</strong></a></p>.<p>Bharat Biotech said the overall rate of adverse events observed with Covaxin was lower than evident in other Covid-19 vaccines. “Safety analysis demonstrates adverse events reported were similar to placebo, with 12 % of subjects experiencing commonly known side effects and less than 0.5 % of subjects feeling serious adverse events”</p>.<p>In the second interim analysis from Phase-3 trials put out in April, Bharat Biotech and ICMR stated that Covaxin was showing overall clinical efficacy of 78 percent and 100 percent efficacy against severe Covid-19 infections.</p>.<p><strong>Check out DH latest videos:</strong></p>